Literature DB >> 11562709

Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction.

C Britto1, C Silveira, M A Cardoso, P Marques, A Luquetti, V Macêdo, O Fernandes.   

Abstract

Polymerase chain reaction (PCR) was compared with xenodiagnosis performed 20 years after trypanocidal chemotherapy to investigate parasite clearance. Eighty-five seropositive individuals for Chagas disease presenting a positive xenodiagnosis were treated with specific drugs; 37 in the acute phase and 48 in the chronic phase. Fifteen chronic asymptomatic patients received a placebo. Treatment in the acute phase led to PCR negative results in 73% of the cases, while xenodiagnosis was negative in 86%. In the chronic phase, PCR was negative in 65% of the patients and 83% led to xenodiagnosis negative results. Regarding the untreated group (placebo), 73% gave negative results by xenodiagnosis, of which 36% were positive by PCR. Individuals that were considered seronegative (n=10), presented unequivocally negative results in the PCR demonstrating the elimination of parasite DNA. Seventeen individuals had their antibodies titers decreased to such a level that the final results were considered as doubtful and 16 of them presented negative PCR. The molecular method represents a clear advantage over conventional techniques to demonstrate persistent infections in Chagas disease patients that underwent chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562709     DOI: 10.1590/s0074-02762001000600014

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  15 in total

1.  Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients.

Authors:  Wendell S F Meira; Lúcia M C Galvão; Eliane D Gontijo; George L L Machado-Coelho; Karen A Norris; Egler Chiari
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

3.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

Review 4.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

5.  Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.

Authors:  Catalina Muñoz; Inés Zulantay; Werner Apt; Sylvia Ortiz; Alejandro G Schijman; Margarita Bisio; Valentina Ferrada; Cinthya Herrera; Gabriela Martínez; Aldo Solari
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.

Authors:  A L Basquiera; A Sembaj; A M Aguerri; M Omelianiuk; S Guzmán; J Moreno Barral; T F Caeiro; R J Madoery; O A Salomone
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

7.  PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy.

Authors:  Lúcia M C Galvão; Egler Chiari; Andréa M Macedo; Alejandro O Luquetti; Simonne A Silva; Ana Lúcia S S Andrade
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

8.  Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease.

Authors:  Olga Sánchez Negrette; Fernando J Sánchez Valdéz; Carlos D Lacunza; María Fernanda García Bustos; María Celia Mora; Alejandro D Uncos; Miguel Angel Basombrío
Journal:  Clin Vaccine Immunol       Date:  2007-12-05

9.  Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.

Authors:  Ana Fernández-Villegas; María Jesús Pinazo; Concepción Marañón; M Carmen Thomas; Elizabeth Posada; Bartolomé Carrilero; Manuel Segovia; Joaquim Gascon; Manuel C López
Journal:  BMC Infect Dis       Date:  2011-07-31       Impact factor: 3.090

Review 10.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.